Sentences with phrase «reported on the drug»

Although none of the groups reported on drug side effects, while Guo who tested only breastfed infants reported on significant decrease in infant crying, and decrease in depressive symptoms at one month and at two months respectively, Sung who tested both formula fed and breastfed infants reported on increase crying in the probiotic treated infants (particularly in the formula fed infants) compared to placebo with no effect on maternal depressive symptoms.

Will he find his courage again and look at the new report on drugs?

The panel included five contributors to a President's Council of Advisors on Science and Technology report on drug innovation, which in 2012 offered a list of recommendations for improving the drug approval process.

The extended online version of your report on drug trials carried out on pet dogs in the US quotes me...

Meanwhile, the inaccuracies and sensationalism of the mainstream media in its approach to reporting on drugs can only hasten its already diminishing relevance to the generation that is more likely to trust what it reads on Twitter and Facebook.

School - based initiatives similar to programs that have kept 7th graders from taking up cigarette smoking offer a more promising means of countering adolescent drug use than do tougher drug - enforcement laws, according to a new report on drug - abuse prevention.

Earlier this year, ABC7 (WJLA) in Washington aired an investigative report on the drug being found in Gravy Train canned food.

He's reported on the drug war, national politics, and same - sex salsa.

Through my experience, I have become well versed in conducting in - depth research, analyzing data, and managing databases to assess and report on drug benefits and risks prior to market release.

Not exact matches

Drugmaker Merck reported a better - than - expected first - quarter profit on Tuesday, helped by a more than 150 percent rise in sales of cancer drug Keytruda.

NEW YORK, May 1 - Pfizer Inc on Tuesday reported lower - than - expected first - quarter revenue as demand for some key drugs and international sales fell short of estimates, sparking a 5.1 percent drop in shares of the largest U.S. drugmaker.

David Debolt, reporting for East Bay Times says, «Oakland ramped up its counterattack to the U.S. war on drugs, expanding its one - of - a-kind program to help people jailed for marijuana crimes enter the booming cannabis industry.»

The $ 1.1 billion Alphabet - backed Silicon Valley unicorn 23andMe just pulled off a milestone feat: On Thursday, the Food and Drug Administration (FDA) said the company could sell its genetic tests and accompanying health risk reports for ten different diseases directly to consumers.

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

Fears that the retail shelf space coming with the Whole Foods buyout could make it easier for Amazon to carry through on its reported plans to branch into the pharmacy and drug delivery business.

The New York Times and CBS News, citing unnamed officials briefed on the matter, reported they included overseeing a hostile work environment as the White House doctor, allowed the overprescribing of drugs and drank on the job.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Not only have sales been meager, but the pill and its manufacturer — Valeant Pharmaceuticals (vrx)-- rate poorly on several measures that should be of concern to women and doctors, according to an advocacy group that on Thursday released a report card for the drug's one - year anniversary.

In 2014, she revealed the agonizing decision - making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.

The decision comes on the heels of a new report from the National Center for Health Statistics, an agency of the Centers For Disease Control and Prevention, that shows the rate of estimated drug overdose deaths increased in the third quarter of 2016 and outpaced the rate of drug - related deaths over the same period in 2015.

The U.S. filed its first charges in a generic drug price - fixing probe on Wednesday, according to a report.

CVS Health reported a 4.8 percent rise in quarterly profit on Wednesday, helped by higher sales of prescription drugs at its stores.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

KFC, China's biggest restaurant chain with more than 4,000 outlets and plans to open 700 more this year, was hit hard by a report in December 2013 that some poultry suppliers violated rules on drug use in chickens.

The cellular health of the mice that took the drug was also improved, as was inflammation that was previously seen on their brains, reports Genetic Engineering and Biology News.

The article described how an internal investigation conducted by a company executive, Dinesh Thakur, who went on to become a whistleblower, reported appalling deceit: Ranbaxy scientists substituted cheaper, lower - quality ingredients in place of better ingredients, manipulated test parameters, and even bought brand - name drugs and used them in place of their own generics to win FDA approval.

The latest pharma innovation report from Deloitte holds some pretty grim news for pharma: returns on R&D investments by large cap companies slid to a mere 3.7 % in 2016, down from the 10.1 % returns seen in 2010 (although the cost of bringing a drug to market is beginning to stabilize).

As I've previously reported, Roivant and its federation of biopharma companies focused on developing drugs in specific disease spaces is attempting a very new form of pharmaceutical R&D.

The report also included accounts of the CEO picking on employees about their weight and spreading rumors about their sexual habits or drug problems.

The report depicts shifts in cartel presence in the US — most notably the disappearance of the Knights Templar, which «is still regarded as a viable [transnational criminal organization] in Mexico,» though the «DEA assesses it does not have a major impact on the drug trafficking landscape within the United States.»

April 9 - The U.S. Justice Department will allow German drugs and pesticides group Bayer AG to acquire Monsanto Co in a $ 62.5 billion deal, after the companies agreed to sell more assets to win antitrust approval, the Wall Street Journal reported https://on.wsj.com/2GKhEGh on Monday.

According to a report from Bloomberg, only 227 prescriptions for the drug had been written by November, three months after it had been on the market.

The White House report on the epidemic says that 142 Americans die of drug overdoses every day, and urges measures like federal legislation that would boost widespread adoption of naloxone, an opioid overdose antidote.

That number is based on prescriptions by morphine milligram equivalents, a metric that takes into account the strength and dosage of drugs, but the total number of filled opioid prescriptions also dropped by 10.2 % per month, according to the report.

CNBC's Diana Olick reports on how real estate agents are protecting themselves from people who are booking home tours for easy access to drugs.

As Businessweek reports, the case centers on a Japanese pharmaceutical company called Asahi, which licensed a drug called Fasudil to the San Francisco - based company CoTherix in 2006.

«The data makes it clear that ending the War on Drugs will not alone end mass incarceration, but that the federal government and some states have effectively reduced their incarcerated populations by turning to drug policy reform,» the report says.

In a 2015 report on national drug threats, DEA officials stated that fentanyl was «unlikely to assume a significant portion of the opioid market.»

CreditCards.com (2013) reported, «nearly all banks and credit card companies, reluctant to run afoul of federal drug and banking laws that remain on the books, refuse to do business with even state - licensed sellers of marijuana.

Novartis (nvs) chief Joe Jiminez has been touting a pricing model that incorporates drugs» real - world outcomes for years, stressing the importance of placing patients before profits; Regeneron (regn) head honcho Len Schliefer had some tough words for fellow panelists from Eli Lilly (lly) and Pfizer (pfe)(who argued that media reports about their own continued reliance on price increases to drive revenues is misleading) during Forbes» event.

«Humana is potentially an attractive asset for Walmart as it would help diversify its revenue stream,» Cantor Fitzgerald health insurance analyst Steven Halper wrote in a recent report, noting that the retailer and insurer already partner on a co-branded Medicare prescription drug plan.

U.S. Attorney General Jeff Sessions has made no secret of his contempt for marijuana use, and his Department of Justice is on the verge of releasing a report that many in the burgeoning legal cannabis industry fear will propose prosecuting people engaging in marijuana sales — even if they are in states that have legalized the drug locally.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

As Fortune reported in an in - depth report on the crisis in September, an American is now far likelier to die of a drug overdose than in a car crash.

Top - selling drugs are ranked based on sales or revenue reported for 2014 by biopharma companies in press announcements, annual reports, investor materials, and / or conference calls.

Musk also said in his Silicon Valley burn, as reported via Re / code, that Judge has obviously never attended Burning Man, the overpriced annual hipster love / drug / artfest on the dusty dunes of Nevada's Black Rock Desert that corporations love to sponsor.

Earlier this month, the company confirmed it was considering a bid for rare disease drug maker Shire Plc (SHP.L) after Reuters reported on its interest.

Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong.

There are a lot of serious issues in the United States, and the inclination to try to stay serious and talk about guns, trade, Medicaid, or drug overdoses rather than reports of the president's alleged past affairs with porn actresses and Playboy playmates is understandable and, on some level, laudable.

(Reuters)- Celgene Corp on Thursday reported third - quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.